JP2022033855A5 - - Google Patents

Download PDF

Info

Publication number
JP2022033855A5
JP2022033855A5 JP2021194601A JP2021194601A JP2022033855A5 JP 2022033855 A5 JP2022033855 A5 JP 2022033855A5 JP 2021194601 A JP2021194601 A JP 2021194601A JP 2021194601 A JP2021194601 A JP 2021194601A JP 2022033855 A5 JP2022033855 A5 JP 2022033855A5
Authority
JP
Japan
Prior art keywords
acid sequence
nucleic acid
composition
promoter
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021194601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022033855A (ja
JP7315284B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2017/033815 external-priority patent/WO2017201527A2/en
Application filed filed Critical
Publication of JP2022033855A publication Critical patent/JP2022033855A/ja
Publication of JP2022033855A5 publication Critical patent/JP2022033855A5/ja
Priority to JP2023044658A priority Critical patent/JP2023078338A/ja
Application granted granted Critical
Publication of JP7315284B2 publication Critical patent/JP7315284B2/ja
Priority to JP2025028446A priority patent/JP2025078652A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021194601A 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法 Active JP7315284B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023044658A JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662339182P 2016-05-20 2016-05-20
US62/339,182 2016-05-20
US201662421665P 2016-11-14 2016-11-14
US62/421,665 2016-11-14
PCT/US2017/033815 WO2017201527A2 (en) 2016-05-20 2017-05-22 Gene therapy methods for age-related diseases and conditions
JP2018560974A JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018560974A Division JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023044658A Division JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法

Publications (3)

Publication Number Publication Date
JP2022033855A JP2022033855A (ja) 2022-03-02
JP2022033855A5 true JP2022033855A5 (enExample) 2022-09-16
JP7315284B2 JP7315284B2 (ja) 2023-07-26

Family

ID=60326179

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法
JP2021194601A Active JP7315284B2 (ja) 2016-05-20 2021-11-30 加齢関連疾患及び症状の遺伝子治療法
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A Pending JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018560974A Active JP7632835B2 (ja) 2016-05-20 2017-05-22 加齢関連疾患及び症状の遺伝子治療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023044658A Pending JP2023078338A (ja) 2016-05-20 2023-03-20 加齢関連疾患及び症状の遺伝子治療法
JP2025028446A Pending JP2025078652A (ja) 2016-05-20 2025-02-25 加齢関連疾患及び症状の遺伝子治療法

Country Status (9)

Country Link
US (2) US12281154B2 (enExample)
EP (1) EP3458585A4 (enExample)
JP (4) JP7632835B2 (enExample)
CN (2) CN109844124B (enExample)
AU (2) AU2017268469C1 (enExample)
BR (1) BR112018073861A2 (enExample)
CA (1) CA3025020A1 (enExample)
MX (2) MX2018014256A (enExample)
WO (1) WO2017201527A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11208443B2 (en) * 2017-02-14 2021-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. NAF-1 derived peptides and uses thereof
EP4653536A2 (en) * 2017-03-17 2025-11-26 Adverum Biotechnologies, Inc. Compositions and methods for enhanced gene expression
JP7778469B2 (ja) * 2017-05-24 2025-12-02 ウニベルシダッド アウトノマ デ バルセロナ 線維芽細胞増殖因子２１（ｆｇｆ２１）コーディング配列を含むウイルス発現コンストラクト
CN119390821A (zh) 2017-08-15 2025-02-07 伊兰科美国公司 兽药用IgG Fc变体
US11530433B2 (en) * 2017-10-20 2022-12-20 President And Fellows Of Harvard College Artificial secretion peptides for heterologous protein production
US11807850B2 (en) 2017-12-06 2023-11-07 Klogenix Llc Compositions and methods for modulating gene expression
CA3110290A1 (en) * 2018-08-30 2020-03-05 Research Institute At Nationwide Children's Hospital Gene therapy for the treatment of galactosemia
BR112021006977A2 (pt) * 2018-10-18 2021-07-27 Kindred Biosciences, Inc. variantes fc com ligação alterada a receptor fc neonatal (fcrn) para uso veterinário
US12134772B2 (en) 2018-11-21 2024-11-05 Advantage Therapeutics, Inc. Increasing gene expression
CA3120923A1 (en) * 2018-11-26 2020-06-04 Universitat Autonoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy
US11505797B2 (en) 2019-05-23 2022-11-22 Christiana Care Health Services, Inc. Gene knockout of variant NRF2 for treatment of cancer
US12203070B2 (en) 2019-05-23 2025-01-21 Christiana Care Gene Editing Institute, Inc. Gene knockout of NRF2 for treatment of cancer
JP2022536692A (ja) 2019-06-11 2022-08-18 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 調節不全の血漿カリクレインによって媒介される疾患の治療のための抗体のアデノ随伴ウイルスベクター送達
US10653731B1 (en) * 2019-07-15 2020-05-19 Vigene Biosciences Inc. Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
KR102281858B1 (ko) 2019-09-11 2021-07-26 주식회사 쎌바이오텍 유산균 유래 p8 단백질의 발현 컨스트럭트를 포함하는 대장 질환의 치료 또는 예방용 조성물
EP4028532A1 (en) * 2019-09-13 2022-07-20 Rutgers, the State University of New Jersey Aav-compatible laminin-linker polymerization proteins
EP4048800A1 (en) 2019-10-23 2022-08-31 Shire Human Genetic Therapies, Inc. Adeno-associated virus vectors based gene therapy for hereditary angioedema
CN110894508B (zh) * 2019-10-31 2021-08-06 内蒙古大学 一种调控白色脂肪棕色化的基因Adra1a的应用
CN115515645A (zh) * 2019-12-05 2022-12-23 哈佛学院董事及会员团体 治疗骨关节炎的方法
JP7588466B2 (ja) * 2020-01-22 2024-11-22 旭化成メディカル株式会社 パルボウイルスの生産方法
EP4142758A4 (en) * 2020-04-28 2025-02-26 President and Fellows of Harvard College High efficiency gene delivery system
JP2023526049A (ja) * 2020-05-13 2023-06-20 リソジェン Ｇｍ１ガングリオシド－シスおよび他の障害を処置するための組成物および方法
WO2021239815A1 (en) * 2020-05-26 2021-12-02 Universitat Autònoma De Barcelona Fibroblast growth factor 21 (fgf21) gene therapy for central nervous system disorders
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途
WO2022115739A2 (en) * 2020-11-30 2022-06-02 Cellular Longevity, Inc. Lnp and liposome compositions for longevity in mammals and methods of using the same
CN116829595A (zh) 2020-12-16 2023-09-29 武田药品工业株式会社 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送
KR102590276B1 (ko) * 2021-01-04 2023-10-16 부산대학교 산학협력단 조직 특이적 발현을 위한 융합 프로모터 및 이의 용도
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113088531B (zh) * 2021-03-25 2023-10-17 四川省药品检验研究院(四川省医疗器械检测中心) 牛源性成分定量分析标准质粒、制备及检测方法及应用
US20240124541A1 (en) * 2021-04-12 2024-04-18 University of Florida Research Foundation, Incorprated Compositions and methods for treating obesity
JP2022169389A (ja) * 2021-04-27 2022-11-09 国立大学法人北海道大学 イヌＴＧＦ－β受容体ＩＩ
US20220401583A1 (en) * 2021-06-16 2022-12-22 BioViva USA, Inc. Treatment of age-related cognitive decline using genetically modified viral vectors
US20230018934A1 (en) * 2021-07-16 2023-01-19 Genflow Biosciences Srl Method of in vivo administration of the coding sequence of the sirt6 gene via adeno-associated virus
EP4408482A4 (en) * 2021-09-29 2025-11-12 Sirt6 Ltd METHOD OF TREATING A DISEASE
CN114921480A (zh) * 2022-06-09 2022-08-19 国科宁波生命与健康产业研究院 一种骨细胞Terc基因敲除小鼠模型的构建方法
WO2024064785A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for familial partial lipodystrophy
WO2024064796A2 (en) * 2022-09-21 2024-03-28 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
EP4590693A2 (en) * 2022-09-21 2025-07-30 Rejuvenate Bio Inc Gene therapy methods for treating mitral valve disease
CN116790610B (zh) * 2023-05-18 2024-09-20 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物
EP4566618A1 (en) * 2023-12-06 2025-06-11 ADvantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight
WO2025109173A1 (en) 2023-11-22 2025-05-30 Advantage Therapeutics, Inc. Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
TR199902878T2 (xx) 1997-04-18 2000-02-21 Biogen,Inc. Tip II TGF-Beta Resept�r/�m�noglob�lin sabit b�l�m f�zyon proteinleri.
US7622300B2 (en) * 1998-06-03 2009-11-24 Kappes John C Trans-lentiviral vector particles and transduction of eukaryotic cells therewith
US7419829B2 (en) * 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
AU2003209226A1 (en) * 2002-01-11 2003-07-30 Michael Tennant Adiponectin gene therapy
US8158589B2 (en) * 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US7511056B2 (en) * 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
ES2361269T3 (es) * 2005-04-22 2011-06-15 Eli Lilly And Company Anticuerpos especificos de tgf beta 1.
DE102005061840A1 (de) * 2005-12-23 2007-06-28 Merck Patent Gmbh Triazolderivate
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US20100190697A1 (en) * 2006-09-13 2010-07-29 The Trustees Of Columbia University In The City If Undercarboxylated/uncarboxylated osteocalcin increases beta-cell proliferation, insulin secretion, insulin sensitivity, glucose tolerance and decreases fat mass
WO2008157367A1 (en) * 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
US8236557B2 (en) * 2008-05-28 2012-08-07 University Of Missouri-Columbia Hybrid-AAV vectors to deliver large gene expression cassette
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
IL300733B1 (en) * 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
AR083445A1 (es) * 2010-10-14 2013-02-27 Univ Mie siARN CONTRA LA FIBROSIS
DK2455104T3 (da) * 2010-11-19 2013-10-14 Universitaetsklinikum Freiburg Biofunktionaliserede stimulusafhængige opløselige PEG-hydrogeler
EP2548570A1 (en) * 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2750695A2 (en) * 2011-08-31 2014-07-09 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
TWI593708B (zh) * 2011-09-26 2017-08-01 諾華公司 治療代謝病症之融合蛋白質
CN103203027A (zh) * 2011-11-03 2013-07-17 阳明大学 用于治疗和预防老化相关症状的方法和组分
WO2013111081A1 (en) 2012-01-24 2013-08-01 Bar-Ilan University Treatment of disease by modulation of sirt6
CN103665166A (zh) * 2012-09-03 2014-03-26 福又达生物科技股份有限公司 犬融合干扰素
WO2014152993A1 (en) * 2013-03-14 2014-09-25 The Board Of Regents Of The University Of Oklahoma Use of klotho nucleic acids or proteins for treatment of diabetes and diabetes-related conditions
JP2017513833A (ja) * 2014-04-08 2017-06-01 ユニヴァーシティー オブ サザン カリフォルニア Ｖｉｉ型コラーゲンフィブロネクチンｉｉｉ型様リピートを有するポリペプチド組成物ならびに創傷の閉鎖および治癒のための治療方法
KR20150135148A (ko) * 2014-05-23 2015-12-02 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
CN107108710B (zh) * 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
US10882894B2 (en) * 2015-08-11 2021-01-05 Anie Philip Peptidic TGF-beta antagonists

Similar Documents

Publication Publication Date Title
JP2022033855A5 (enExample)
JP2025078652A5 (enExample)
IL299325B2 (en) Acid-alpha glucosidase variants and uses thereof
JP2020114235A5 (enExample)
JP2022190081A5 (enExample)
JP2019519221A5 (enExample)
IL292264B1 (en) Aav transfer cassette
JP2020520643A5 (enExample)
JP2018522529A5 (enExample)
JP2008506389A (ja) Ａａｖベクター組成物および免疫グロブリンの発現の増強のための方法ならびにその使用方法
JPWO2020106916A5 (enExample)
JP2018526003A (ja) イヌの癌を治療するためのキメラａａｖ−抗ｖｅｇｆ
JP2003505033A5 (enExample)
JP2024099770A5 (enExample)
JP2023065516A5 (enExample)
JPWO2021067448A5 (enExample)
JPWO2019161059A5 (enExample)
JPWO2020033473A5 (enExample)
JPWO2020214609A5 (enExample)
JPWO2019165050A5 (enExample)
JPWO2020168222A5 (enExample)
JPWO2020243651A5 (enExample)
JPWO2020186207A5 (enExample)
JPWO2021113642A5 (enExample)
JPWO2020041498A5 (enExample)